GlassScriptPhysician profile
Bahram Ahmadi
NPI 1003849001
$14,485.47
in general payments reported to CMS, 2019-2025
46 companies · $935 in 2025
The $935 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,482 · 2020: $1,178 · 2021: $2,030 · 2022: $2,230 · 2023: $3,706 · 2024: $1,925 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867 · Consulting Fee: $2,000 · Travel and Lodging: $661 · Education: $38.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.50 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $660.66 |
| Education | $38.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,553.98 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Arena Pharmaceuticals, INC. | $2,000.00 | 2023 | |
| Gilead Sciences, INC. | $1,076.21 | 2019-2025 | |
| Pfizer INC. | $787.78 | 2019-2024 | |
| Olympus Corporation of The Americas | $660.66 | 2024 | Olympus, Disposable Distal Attachment |
| Takeda Pharmaceuticals U.S.A., INC. | $605.00 | 2019-2024 | Entyvio |
| Nestle Healthcare Nutrition INC. | $473.47 | 2020-2023 | |
| Janssen Biotech, INC. | $385.82 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Neuraxis, INC. | $374.26 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.10 | 2019-2024 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $264.99 | 2024-2025 | Vowst, Zenpep |
| Allergan, INC. | $248.46 | 2019 | |
| Ironwood Pharmaceuticals, INC | $246.29 | 2020-2023 | Linzess |
| Redhill Biopharma INC. | $242.33 | 2021-2024 | Aemcolo, Talicia, Movantik |
| Shionogi INC | $237.74 | 2019-2020 |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahram Ahmadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.